Nexsen Limited · ASX:NXN
Nexsen — Investor Presentation (December 2025)
15 slides from Nexsen's investor presentation, Dec 8, 2025
Slide 1: ASX Release - Investor Presentation
ASX Release | 8 December 2025 Nexsen Limited (ASX:NXN) (Nexsen or the Company) provides the enclosed investor presentation being delivered this week by the Managing Director Mark Muzzin, and Executive Chairman Reece O’Connell in a non- deal roadshow in the United Kingdom. ASX release authorised by t
Slide 2: Nexsen: Lab on a stick closing global diagnostic gaps
ASX:NXN Nexsen Alab on a stick closing global diagnostic gaps United Kingdom Roadshow - December 2025
Slide 3: Disclaimer
Disclaimer Important information ‘The following disclaimer applies to this investor presentation (Presentation) and you are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this, Presentation. By accepting
Slide 4: Executive Summary
Executive Summary Arapid diagnostics company closing time-critical gaps in global healthcare Nexsen is developing a suite of rapid point-of-care diagnostics that deliver rapid lab-grade results for time- critical conditions traditionally reliant on delayed lab-based testing $ » Rapid diagnostics for
Slide 5: Our mission
Our mission Become a global leader in rapid point-of-care diagnostics, solving globally significant unmet clinical needs with our World first diagnostics platform © We believe that every person, somewhere in the world will benefit from at least one Nexsen test in their lifetime. ” Mark Muzzin Founde
Slide 6: Next-generation Rapid Diagnostics
Next-generation Rapid Diagnostics With a lab on a stick, Nexsen brings speed and accuracy to the front lines © Rapid results Lab-grade accuracy Test results visible in up to 20-minutes, no Trusted results with lab-level sensitivity and delays specificity 4 x) Use at the point-of-care Multiple time e
Slide 7: Benefits to healthcare
Benefits to healthcare Nexsen improves outcomes and eases pressure on health systems Many time-critical conditions still rely on slow, centralised lab testing, delaying treatment and placing pressure on health systems 0 Rapid results drive better patient outcomes When clinicians get answers in minut
Slide 8: Lead Diagnostics
Lead Diagnostics Advancing tests for two conditions with significant clinical demand GSB Rapid Sensor Arapid point-of-care diagnostic tool for detecting Group B Streptococcus in expectant mothers a critical unmet need in maternal health Total addressable market! 132m births annually Kidney Function
Slide 9: Diagnostics Pipeline
Diagnostics Pipeline Expanding suite of tests for globally significant challenges Current pipeline Human Health ¢ GBS Rapid Sensor ¢ Kidney functions test Ag-Tech « Bovine Mastitis a $32 billion problem? Biosecurity Targeting threats to the wine and citrus industry Driven by clinical demand Evolving
Slide 10: Market Opportunity
Market Opportunity Significant near-term and future market opportunity 1. GBS Rapid Sensor 2. Kidney Function Diagnostics 3. Future Opportunities Nexsen diagnostics pipeline includes mM m targets for a range of diverse globally . . significant unmet needs, with large annual births people impacted ma
Slide 11: Progress
Progress Years of R&D complete now advancing market rollout World-class research and innovation Years of dedicated work to deliver lab-grade accuracy in a rapid portable format $8M raised through IPO Recently completed a successful IPO supported by leading institutional investors GBS Rapid Sensor pr
Slide 12: Outlook
Outlook Strategic priorities and growth catalysts for 2026 GBS Rapid Sensor market entry Expand clinical sites for accelerated data collection in support of regulatory submissions Advance Kidney Function Test development Rapidly progress Kidney Function Tests and accelerate go-to-market pathway Addi
Slide 13: Team
Team Led by world-class clinical innovators & commercial experts Mr Reece O'Connell Mr Mark Muzzin Dr Martina Mariano Executive Chairman Founder & Non-Executive Director Managing Director ; | “ ws Prof. Shekhar Kumta Mr Grant Pestell Non-Executive Director & Non-Executive Director Advisory Board Mem
Slide 14: Investment Highlights
Investment Highlights Join us as we become a global leader in rapid point-of-care diagnostics Differentiated ‘lab on a stick’ technology solving global diagnostic gaps Point-of-care diagnostics that deliver rapid, lab-grade accuracy for serious conditions reliant on delayed lab testing Rapid, effici
Slide 15: Contact
Contact Corporate Information Corporate Enquires Media Enquires Company Secretary Nexsen Limited Jane Morgan Management Sonny Didugu p: +612 9174 5388 p: + 61 (0) 4 0555 5618 p: + 612 9174 5388 e: corporate@nexsen.bio e: info@janemorganmanagement.com.au e: sd@nexsen.bio w. nexsen.bio Investor Centre